2 results
Approved WMOCompleted
See protocol page 9This study designed to determine, via continuous monitoring with the Reveal XT implantable cardiac monitor (ICM) or newer approved version, the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for…
Approved WMOCompleted
Part 1: The primary objective of this study is to evaluate the efficacy of natalizumab extended interval dosing (EID) in subjects who have previously been treated with natalizumab standard interval dosing (SID) for at least 12 months, in relation to…